Rare diseases

News

NICE reviews number crunching methods as advanced technologi...

NICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in decision making and dealing with uncertainties in evidence.

Partner Content

Partner Content

Three Interactive Sessions to take place at the Respiratory ...

Interactive Sessions at RDD

Market Access

Hand arranging wooden cubes in a structure rocket shape. Conceptual of business startup and strategy.

Achieving launch excellence in orphan medicines

New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.

News

Under threat from Novartis, Biogen hails new data from SMA d...

Under threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for the muscle wasting disease spinal muscular atrophy, with new data that it hopes persuades

News